3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry lower today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 122 points (-0.7%) at 17,326 as of Friday, Nov. 13, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,130 issues advancing vs. 1,809 declining with 163 unchanged.

The Drugs industry currently sits up 1.6% versus the S&P 500, which is down 0.8%. On the negative front, top decliners within the industry include

Perrigo

(

PRGO

), down 7.3%, and

Novartis

(

NVS

), down 0.6%. Top gainers within the industry include

Mylan

(

MYL

), up 12.3%,

Mallinckrodt

(

MNK

), up 6.3%,

Illumina

(

ILMN

), up 6.7%,

Endo International

(

ENDP

), up 3.8% and

Dr Reddy Laboratories

(

RDY

), up 3.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Sanofi

(

SNY

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sanofi is down $0.45 (-1.0%) to $43.19 on heavy volume. Thus far, 3.0 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $42.86-$43.23 after having opened the day at $43.00 as compared to the previous trading day's close of $43.64.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sanofi researches, develops, and markets various therapeutic solutions. Sanofi has a market cap of $118.1 billion and is part of the health care sector. Shares are down 4.3% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Sanofi

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Sanofi Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Novo Nordisk A/S

(

NVO

) is down $0.43 (-0.8%) to $53.07 on light volume. Thus far, 435,185 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $52.74-$53.36 after having opened the day at $52.77 as compared to the previous trading day's close of $53.50.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $143.0 billion and is part of the health care sector. Shares are up 26.4% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Novo Nordisk A/S Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is down $1.86 (-1.8%) to $102.37 on average volume. Thus far, 5.3 million shares of Gilead exchanged hands as compared to its average daily volume of 12.0 million shares. The stock has ranged in price between $102.28-$104.18 after having opened the day at $104.09 as compared to the previous trading day's close of $104.23.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $154.5 billion and is part of the health care sector. Shares are up 10.6% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Gilead a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...